Search
Filters
Clear AllGender
-
16
-
25
-
1
-
164
Phase
-
1
-
1
-
1
-
5
-
4
-
3
-
152
Age Group
-
194
-
64
Virtual Trials
-
205
-
1
Study Type
-
12
-
2
New Trials
-
206
Loading...
Found 206 results for Neoplasm
A listing of Neoplasm medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Glycosylation of Urinary Exosomes in Prostate and Urothelial Carcinoma
The purpose of this study is to collect a urine sample from patients with prostate and urothelial (bladder) cancer and healthy volunteers who do not have cancer, so that researchers can perform studies on microcellular structures called exosomes that may lead to a new type of urinary biomarker test for …
Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination therapy involving antibodies nivolumab, ipilimumab and panitumumab.
Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
The purpose of this study is to assess the efficacy and safety of a lower dose than is usually given of stereotactic radiosurgery (i.e. Gamma Knife or Linear Accelerator) for brain metastases patients receiving immunotherapy.
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized).
A Phase II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab
This study is being done to test the safety of combining Entinostat with Nivolumab and Ipilimumab. It will also measure the percentage of patients whose tumor shrank after receiving Entinostat with Nivolumab and Ipilimumab.
Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer
The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
The purpose of this study is to find out if the drug, Cabozantinib, is safe and tolerable in pediatric patients with refractory and/or recurrent high grade gliomas (HGG) who have previously received radiation therapy. We are also looking to see if the drug has an effect on the rate at …
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
The purpose of this study is to study two US FDA approved drugs alone and in combination with each other in people who have mCRPC and DNA repair defects.
A Phase 1 Study of Pevonedistat (MLN4924) a Cullin Ligase Inhibitor in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of pevonedistat when giving together with irinotecan hydrochloride and temozolomide in treating patients with solid tumors or lymphoma that have come back after a period of improvement or that do not respond to treatment.
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
Please choose between Voice or SMS based delivery of verification code
or